Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vikram Premkumar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 11, 2019
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?Vikram Premkumar, Raymond Comenzo, Suzanne Lentzsch
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2020
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma PatientsVikram Premkumar, Divaya Bhutani, Suzanne Lentzsch
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|January 21, 2006
Primary large B-cell cardiac lymphomaVikram Premkumar, Behzad Paimany, Aasha S Gopal
Ejhaem|July 18, 2022
Use of daratumumab in high risk multiple myeloma: A meta-analysisVikram Premkumar, Samuel Pan, Suzanne Lentzsch, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Clinical Lymphoma, Myeloma & Leukemia|August 11, 2019
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?Vikram Premkumar, Raymond Comenzo, Suzanne Lentzsch
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2020
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma PatientsVikram Premkumar, Divaya Bhutani, Suzanne Lentzsch
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|January 21, 2006
Primary large B-cell cardiac lymphomaVikram Premkumar, Behzad Paimany, Aasha S Gopal
Ejhaem|July 18, 2022
Use of daratumumab in high risk multiple myeloma: A meta-analysisVikram Premkumar, Samuel Pan, Suzanne Lentzsch, et al.
Pageof 1